Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69…